Tataa Developed Technologies

TATAA-DEVELOPED TECHNOLOGIES

TATAA Technologies and Innovations

TATAA researchers support our customers with technologies, products, and unique solutions that enable processes that reduce costs and enhance reliability in bringing their products and treatments to the clinics.

HISTORY OF INNOVATION

TATAA Biocenter has a history of innovations

Researchers behind TATAA were among the pioneers developing quantitative real-time PCR and later single-cell, multiway, intracellular, and multimodal profiling. The DeltaAmp assays to assess degradation, exogeneous spike-in controls to assess inhibition, ValidPrime and Alu-assays to assess contamination, interplate calibrators to eliminate inter-run variation, and reference gene panels are among the tools developed to ascertain highest possible quality of the measured data.

We co-authored the MIQE Guidelines, which is the most cited paper in molecular diagnostics to date, and the dMIQE guidelines. TATAA is also member of the CANCER-ID and SPIDIA consortia who contributed to numerous ISO and CEN guidelines. TATAAs extensive experience is disseminated to the community through our popular hands-on courses.

Two-Tailed PCR

Short nucleic acids such as microRNAs are way too short to be targeted by two conventional primers required for PCR. Current methods therefore extend short nucleic acid targets by some means prior to amplification. This, however, compromises the sensitivity and the specificity of the assay. TATAA has found a solution. In Two-Tailed PCR a single molecule, designed with a hair-pin structure, hybridizes with both its termini, referred to as hemiprobes, to the target. Each hemiprobe alone is too short to bind but being part of the same molecule binding is cooperative and their combined affinity is sufficient. This leads to greater sensitivity but also superior specificity as sequence variation has much greater impact in the short hemiprobe binding region.

Play Video

Direct Blood Genotyping (DBG)

Genetic testing is typically performed on venous blood samples collected at Doctor’s office, sent to a central laboratory that extracts the DNA and analyses it. Result is sent to the Doctor, who calls back the patient and prescribes drugs and decides treatment supported by the test result. TATAAs Direct Blood Genotyping (“DBG”) allows genetic testing to be performed Point of Care at Doctor’s office. No extraction needed. Furthermore, capillary blood is sufficient, which makes the entire process simple and convenient. In difference to other companies who have tried and failed, we focus on tests that really work and have been extensively validated.